A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Acronyms POM Renal
- Sponsors Celgene Corporation
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Planned End Date changed from 1 Jun 2021 to 11 Jun 2021.
- 13 Mar 2017 Planned primary completion date changed from 1 Jun 2021 to 11 Jun 2021.